Pear Therapeutics Wins Fierce Innovation Life Science Award for reSET® Prescription Digital Therapeutic
First FDA-Cleared Prescription Digital Therapeutic Recognized in Digital Health Solution Category
BOSTON, and SAN FRANCISCO, December 12, 2017– Pear Therapeutics, the leader in prescription digital therapeutics, has won a Fierce Innovation Award in the Digital Health Solution category for reSET®, the first FDA-cleared prescription digital therapeutic to treat any disease. In randomized clinical studies, reSET demonstrated improvement in the outcomes of abstinence and treatment retention in patients with substance use disorder (SUD). Pear was also selected as “Best in Show” for Best Outsourcing Partner.
“We are honored to be acknowledged by our peers,” said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. “Prescription digital therapeutics represent an entirely new treatment modality to treat diseases with high unmet medical needs. Looking forward, we see a clinically-validated and regulated approach becoming standard for any digital therapeutic intended to treat disease.”
reSET is a 12-week duration, FDA-cleared prescription digital therapeutic to be used in conjunction with standard outpatient treatment for SUD. It has demonstrated increased abstinence from a patient’s substances of abuse during treatment and increased patient retention in the outpatient treatment program, when compared to current standard of care treatments.
Pear’s product pipeline also includes reSET-O™, which recently received an Expedited Access Pathway (EAP) designation, now known as the Breakthrough Devices Program, from the FDA. reSET-O is poised to be the first prescription digital therapeutic to be used as an adjunct to pharmacotherapy designed to treat opioid use disorder. The company is also advancing its pipeline across other serious medical conditions including schizophrenia (Thrive™), combat post-traumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder and insomnia.
The Fierce Innovation Awards: Life Sciences Edition is an awards program from the publisher of FierceBiotech and FiercePharma designed to showcase outstanding innovation that is driving improvements and transforming the biotech, digital health and pharma industries. Fierce Innovation Award applications are reviewed by an exclusive panel of judges who base their decision on effectiveness, technical innovation, competitive advantage, financial impact and true innovation. Pear was selected from among four finalists in digital health innovation for its ability to have a major impact on the industry.
About Prescription Digital Therapeutics
Prescription digital therapeutics are clinically validated, FDA-cleared software interventions that demonstrate safety and efficacy in randomized clinical trials to treat disease. They are designed to enhance clinical outcomes, and where clinically relevant may be combined with current treatment regimens including approved drug or device therapies. Prescription digital therapeutics usually include patient-facing applications, clinical assessment and outcomes tracking, clinician monitoring dashboards and HIPAA-compliant data storage.
About Pear Therapeutics
Pear Therapeutics is the leader in FDA-cleared prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-cleared 12-week interval prescription therapeutic for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET®-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (Thrive™), combat posttraumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia, for which Pear intends to obtain FDA clearance. For more details, please see www.peartherapeutics.com.
FierceMarkets, a division of Questex, LLC, is a leader in B2B e-media, providing information and marketing services in the telecommunications, life sciences, healthcare, IT, energy, government, finance, and retail industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets’ wide array of digital publications reaches more than 2 million executives in more than 100 countries.
Karen Sharma or Stefanie Tuck
MacDougall Biomedical Communications